Major pharmaceutical companies Bristol Myers Squibb, Takeda, and Astex have joined forces to pool proprietary structural biology data sets for training OpenFold3, an AI platform dedicated to drug discovery. This collaboration aims to advance structural prediction capabilities and reduce drug development timelines by leveraging shared datasets. The initiative underscores the growing importance of artificial intelligence and data sharing in pharmaceutical research innovation.